Biotechnology and medicine today aims to not only cure the diseases of old age but to actually cure the root cause -- aging itself.
This sounds like a remarkable feat, but scientific insights in animal models give us clear evidence that it will be the next big step in treating chronic diseases.
In several groundbreaking studies, mice became younger by all measures when they were treated with a gene that elongates their telomeres. Monkeys became stronger when given genes that enhance muscle growth. Rodents lived longer and looked and acted younger when old damaged cells were removed. In addition, the lifespans of several model organisms, from worms, fish, flies, and rodents, have been extended using gene modulation.
Age reversal technologies face challenges when it comes to proving they are effective in large organisms. The biology of human whole-body age reversal is both scientifically cumbersome and cost prohibitive.
In order to better assess outcomes, Integrated Health Systems, their affiliated medical doctors, and BioViva USA are teaming up to create treatments to treat organ-specific diseases like chronic kidney disease (CKD), liver failure, and dementia.
This team of companies, scientists and clinics will ensure patient data turns into meaningful information. Together, they will help patients access therapies, help doctors keep up to date with the most recent technology, and asses the data on patient outcomes.
Looking at the effects of organ-specific failures now gives us insight into a world of chronic disease, including aging.
Today CKD affects 10% of the global population. Approximately 2 million people worldwide are currently receiving dialysis or require a kidney transplant to stay alive. In the United States alone, 3.9 Million or 1.6% of Americans have diagnosed liver disease.
Worldwide, around 50 million people suffer from dementia, with nearly 10 million new cases every year. These three diseases alone can drive invaluable data in regenerative medicine. Organ-specific therapies will be easier to evaluate and make it simpler to assess future therapies. Organ-specific treatments are an example of where regenerative medicine can show its power.
If we focus on those treatments, gene and cell therapies may accelerate medical data relevant to cures. Along the way, we will help millions of people. With adaptive consensual trials, patients can gain access to the gene and cell therapies that address their specific organ’s disease.
Gene therapy offers long-term potential for patients, but the technology is new, and many outcomes are unknown.
These treatments are not inexpensive, gene therapy is a high-end treatment with the potential to be a long-term solution. But Integrated Health Systems has reduced the cost of entry to patients with starting treatment costs of $20,000 and up.
These therapies are cutting edge, overviewed by medical doctors - and by bioinformaticians who collect and analyze the scientific data. Your data could figure in the next big scientific paper, or better yet, originate a future treatment that will extend healthy lives for millions… beginning with yourself.